SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - North America EU edition | APAC edition

News > Manufacturers

Read more breaking news

 

 

Study supports safety of pomegranate metabolite, urolithin A

Post a comment

By Stephen Daniells+

11-Aug-2017
Last updated on 11-Aug-2017 at 19:05 GMT2017-08-11T19:05:40Z

© iStock/max_st
© iStock/max_st

Extensive toxicological data supports the safety of urolithin A, a metabolite from pomegranate compounds and an emerging ingredient positioned for its anti-inflammatory properties and for boosting mitochondrial and muscle function.

Urolithin A is a compound generated by gut microflora from ellagitannins. The compounds are hydrolyzed in the stomach into ellagic acid, which is subsequently converted by the gut microflora into urolithin A. However, not everyone has the right microflora to be able to make the metabolite.

As reported last year by NutraIngredients-USA,  start-up life sciences company Amazentis has developed a method to deliver finely calibrated doses of urolithin A. Preliminary data published in Nature Medicine  indicated that urolithin A may improve mitochondrial function by stimulating mitophagy, a process by which damaged mitochondria are recycled to permit a renewal with healthy mitochondria. These potent beneficial effects were observed in C. elegans, mammalian cells and rodents.

Safety data

Scientists from Exponent, Inc. and Amazentis have now reported that the compound does not, “indicate any target organ toxicities at the histopathological level, nor any specific toxic mechanisms,” when tested in repeated dose 28- and 90-day studies. The data also showed there was no genotoxicity after oral consumption.

The scientists concluded that, based on their data the no observable adverse effect level (NOAEL) was the highest dose tested, equivalent to 3451 mg per kilogram of body weight per day in males and 3826 mg per kg of body weight per day in females.

“This study describes for the first time the safety profile of direct oral exposure to [urolithin A] in preclinical models using an extensive battery of tests,” they wrote in Food and Chemical Toxicology .

Safety, bioavailability, and biological activity

In addition to the toxicological studies, data from a Phase 1 trial in healthy elderly individuals presented at the recent International Conference on Frailty and Sarcopenia Research (ICFSR) in Barcelona, Spain supported the safety, bioavailability, and biological activity of the compound in healthy elderly individuals.

The trial found that oral supplementation with urolithin A did not result in any serious or any product-related non-serious adverse events. The data also supported that urolithin A was bioavailable to blood and skeletal muscle, and that it upregulated mitochondrial gene expression in elderly skeletal muscle tissue.

For more information, please read our earlier article HERE .

Source: Food and Chemical Toxicology
Published online ahead of print, doi: 10.1016/j.fct.2017.07.050
“Safety assessment of Urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant derived ellagitannins and ellagic acid”
Authors: J. Heilman et al. 

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Related products